CAMBRIDGE, MA (PRWEB) February 26, 2015
Nanobiosym Diagnostics®, a leading global nanotechnology company, today announced its CEO Dr. Anita Goel will be joining forces with cloud computing pioneer Paul Maritz to further accelerate Nanobiosym’s initiative to democratize global healthcare. The two leaders will harness the latest nanobiophysics, cloud computing, big data and information communications technologies to deliver an entirely new set of tools that can eradicate Ebola and prevent future pandemics.
With his recent investment in Nanobiosym Diagnostics, Maritz has joined the company’s exclusive circle of investors and Nanobiosym Diagnostics’ distinguished Advisory Board of leading-world experts in business, science, medicine and technology.
“I am delighted to welcome Paul Maritz to our Board,” said Nanobiosym Diagnostics Chairman and CEO, Dr. Anita Goel, MD, PhD, a Harvard and MIT-trained physicist and physician. “Our mission at Nanobiosym Diagnostics is to provide tools so that anyone, anywhere and at any time can have instantaneous access to information about their own health. Paul’s world-class leadership and expertise in cloud computing and big data will help us exponentially amplify the number of lives we can save with our Gene-RADAR® platform.”
Dr. Goel and Nanobiosym Diagnostics developed Gene-RADAR®, a nanotechnology-based device that enables real-time mobilized diagnosis of any disease or condition with a genetic fingerprint. Dr. Goel’s vision is to give patients worldwide real-time access to their own diagnostic information through low-cost mobile devices capable of detecting disease from a single drop of blood or saliva. By combining the data streaming from its Nanobiophysics-based sensors with cloud-based surveillance systems, Nanobiosym is empowering governments, non-governmental organizations, healthcare providers and individuals with real-time diagnostic data and analytics about their own health.
“I’m very excited to join Nanobiosym Diagnostics’ Advisory Board and to have the opportunity to work closely with Dr. Goel to build the tools needed to deliver the next generation of healthcare infrastructure to the world,” said Maritz. “If Gene-RADAR® were more broadly deployed in the developing world, the recent Ebola epidemic would have likely seen a very different outcome. The combination of game-changing technologies like Gene-RADAR®, with big data and cloud computing solutions can immediately distribute medical diagnoses and alerts worldwide. This can stop deadly pathogens before they explode into pandemics and, in effect, re-write the rules of global healthcare.”
About Nanobiosym Diagnostics
Nanobiosym Diagnostics commercializes breakthrough technologies at the nexus of physics, biomedicine and nanotechnology. Its Gene-RADAR® technology platform empowers people worldwide with rapid, accurate and portable diagnostic information about their own health. Gene-RADAR® can detect any disease with a genetic fingerprint in real-time with gold standard accuracy without the need for constant electricity, running water or highly trained personnel. See more at http://www.nanobiosym.com | About Dr. Anita Goel | About Paul Maritz
# # #
Nanobiosym and Gene-RADAR are registered trademarks of Nanobiosym.
For more information, contact:
Tim Hurley/Jessica Branco
Matter Communications for Nanobiosym